Thiophenylaminoimidazolines as IP antagonists

A compound of the formula (II):

• wherein:
• A is:
• —O—;
• or —S—;
• m is 0 or 1;
• n is from 1 to 3;
• R2 is:
• hydrogen;
• alkyl;
• alkoxy;
• haloalkyl;
• or halogen;
• R4 is:
• isopropoxy;
• trifluoromethyl;
• ethoxycarbonyl;
• hydroxycarbonyl;
• nitro;
• methanesulfanyl-amino;
• hydroxymethyl;
• methoxycarbonyl-methyloxy;
• morpholin-4-yl-carbonyl-methyloxy;
• morpholin-4-yl-carbonyl;
• morpholin-4-yl-methyl;
• ethoxy-acetoacetamido;
• cyclohexyl-methyloxy;
• phenoxyethyl-carbonylamino;
• phenylethyl-carbonylamino;
• aminocarbonyl;
• isopropoxy-carbonyl;
• phenyl-carbonyl;
• phenylmethylamino-carbonyl;
• 2,2,2-trifluoroethyloxymethyl;
• phenoxy;
• hydroxycarbonyl-methyloxy;
• 2-(ethoxycarbonyl)-ethyl;
• 2-(ethoxycarbonyl)-ethenyl;
• morpholin-4-yl-carbonyloxy-methyl;
• 4-phenylpiperazin-1-yl-methyl;
• or dimethylaminocarbonyloxymethyl;
• and
• R5 is:
• hydrogen;
• alkyl;
• alkoxy;
• halo;
• or haloalkyl;
• or R4 and R5 together form an alkylene dioxy group;
• and
• Ra, Rb, Rc and Rd each independently is hydrogen or alkyl;
• or pharmaceutically acceptable salts, solvates or prodrugs thereof.